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Abstract
Background: The recent H5N1 avian and H1N1 swine-origin influenza virus outbreaks reaffirm that the threat of a world-
wide influenza pandemic is both real and ever-present. Vaccination is still considered the best strategy for protection
against influenza virus infection but a significant challenge is to identify new vaccine approaches that offer accelerated
production, broader protection against drifted and shifted strains, and the capacity to elicit anti-viral immune responses in
the respiratory tract at the site of viral entry. As a safe alternative to live attenuated vaccines, the mucosal and systemic
immunogenicity of an H1N1 influenza (A/New Caledonia/20/99) HA DNA vaccine administered by particle-mediated
epidermal delivery (PMED or gene gun) was analyzed in rhesus macaques.
Methodology/Principal Findings: Macaques were immunized at weeks 0, 8, and 16 using a disposable single-shot particle-
mediated delivery device designed for clinical use that delivers plasmid DNA directly into cells of the epidermis. Significant
levels of hemagglutination inhibiting (HI) antibodies and cytokine-secreting HA-specific T cells were observed in the
periphery of macaques following 1–3 doses of the PMED HA DNA vaccine. In addition, HA DNA vaccination induced
detectable levels of HA-specific mucosal antibodies and T cells in the lung and gut-associated lymphoid tissues of
vaccinated macaques. Importantly, co-delivery of a DNA encoding the rhesus macaque GM-CSF gene was found to
significantly enhance both the systemic and mucosal immunogenicity of the HA DNA vaccine.
Conclusions/Significance: These results provide strong support for the development of a particle-mediated epidermal DNA
vaccine for protection against respiratory pathogens such as influenza and demonstrate, for the first time, the ability of skin-
delivered GM-CSF to serve as an effective mucosal adjuvant for vaccine induction of immune responses in the gut and
respiratory tract.
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Introduction
Current influenza vaccines protect against homologous viruses
but are less effective against antigenic variants and provide little, if
any, protection against a different subtype. In the event of a
pandemic, existing vaccines may be ineffective because the
manufacturing process requires at least 6 months from identifica-
tion of the pandemic strain to distribution which is insufficient
time to prevent wide-scale morbidity or mortality. New vaccine
strategies are therefore needed that can both accelerate production
and provide broader spectrum protection.
DNA vaccines offer a theoretical advantage over conventional
vaccine strategies in that they can be more rapidly developed in
the event of an influenza pandemic following the identification of
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e11021the newly emerging strain. Once the sequence of the relevant
hemagglutinin gene is known, a DNA vaccine can be synthesized
to express the antigen within a week and rapidly scaled up using
bacterial cell culture. In contrast to conventional approaches there
is no need for live influenza virus or large quantities of eggs, and
DNA vaccines could be deployed earlier in the pandemic to more
effectively reduce morbidity and mortality. It is also straightfor-
ward to develop designer vaccines that contain consensus
sequences capable of inducing antibody that cross-neutralizes
drifted or shifted strains of influenza [1]. Importantly, DNA
vaccines have afforded significant protection against heterologous
challenges with genetically drifted strains (e.g., heterosubtypic
immunity) in animal models, an outcome that may be due to their
ability to also induce robust CD8+ cytotoxic T lymphocyte (CTL)
responses against more conserved regions of the virus [1,2,3,4,5].
Such responses may not prevent infection per se, but could reduce
viral load, mediate faster viral clearance, reduce morbidity, and,
importantly for a viral pandemic, prevent mortality.
Particle mediated epidermal delivery (PMED) of DNA vaccines
involves the use of a needle-free device to deliver plasmid vaccines
directly into cells of the epidermis of the skin including both non-
professional (i.e. keratinocytes) and professional antigen presenting
cells (i.e. Langerhans cells) [6,7,8]. PMED influenza DNA vaccines
have been extensively studied in relevant animal models including
mice, ferrets, and swine and have been shown to induce protective
antibody and cytotoxic T cell responses that provided complete
protection against both homologous and drifted strains of influenza
A viruses [9,10,11,12,13,14,15,16]. Importantly, PMED-based
DNA vaccination may prove to be particularly advantageous over
other DNA vaccine delivery methods due to its apparent ability to
induce mucosal immune responses. Strong mucosal immune
responses induced in both the gut and lung by PMED DNA
vaccines have contributed significantly to enhanced and complete
protection against mucosal challenges with both AIDS viruses and
influenza [13,14,17,18,19]. The ability of PMED DNA vaccination
to elicit mucosal immunity is explained by the finding that the
epidermis of the skin can serve as a potent inductive site for mucosal
responses in distal mucosal sites such as lung and gut [20,21,22,23].
PMED influenza DNA vaccines have shown considerable
promise in the clinic. In contrast to DNA vaccines employing
intramuscular needle injection where milligram doses of plasmids
induced poor responses in humans [24,25,26,27], PMED delivery
of 1–4 mg doses of an influenza DNA vaccine stimulated protective
levels of antibody in 100% of the vaccinated subjects, and
responses exceeded the minimum criteria for licensure established
by the Committee for Human Medicinal Products [28]. In a
subsequent phase 1 clinical study where subjects were vaccinated
with a trivalent PMED DNA influenza vaccine and then
challenged with a controlled dose of an H3 influenza virus, the
vaccine was well tolerated, induced anti-hemagglutinin (HA)
antibody responses and provided protection against challenge with
a vaccine efficacy of 53% against upper respiratory tract infection
[29].
Despite these promising data there is still a need to increase the
potency of PMED influenza DNA vaccines in the clinic to provide
protection at or above the 70% protection level seen with trivalent
inactivated influenza vaccines [30]. One method to enhance
potency is to include a genetic adjuvant in the formulation of the
DNA vaccine. Several reports have shown that co-administration of
an adjuvant plasmid expressing the cytokine GM-CSF (granulocyte
macrophage-colony stimulating factor) substantially increased both
the immunogenicity and protective efficacy of DNA vaccines in
mice and nonhuman primates [31,32,33,34,35,36]. GM-CSF is a
pleiotropic cytokine that stimulates the development, proliferation,
and maturation of dendritic cells and monocytes. These antigen
presenting cells are critical mediators for vaccine induction of
immune responses. GM-CSF has been shown to enhance the
ability of influenza DNA vaccines to induce antibody responses
and protection in mice [37,38], but not in the context of influenza
DNA vaccines in either the clinic or a relevant large animal
preclinical model. In addition, the capacity for GM-CSF to
enhance the ability of DNA vaccines to induce mucosal responses
has not been explored. We reasoned that GM-CSF may be a
particularly potent adjuvant for augmenting the immunogenicity
of PMED in both larger animals and the clinic as PMED can
deliver both the vaccine plasmid and adjuvant plasmid directly
into the same antigen presenting cells of the skin [6,39]. In this
study we provide evidence that co-delivery of GM-CSF with an
H1N1 influenza DNA vaccine using a disposable PMED clinical
device substantially increased DNA vaccine potency for induction
of both neutralizing antibody and T cell responses in the highly
relevant preclinical nonhuman primate model. Furthermore, we
show for the first time that GM-CSF, when administered to the
epidermal layer of the skin, can serve as a highly effective
adjuvant for enhancing mucosal T cell responses in both the lung
and gut of rhesus macaques.
Results
Particle-mediated epidermal delivery of influenza DNA
vaccines into nonhuman primates using the ND10
clinical delivery device
DNA plasmids encoding the H1N1/New Caledonia hemagglu-
tinin (HA) gene alone (2.0 mg) (Figure 1A) or co-formulated with
rhesus macaque GM-CSF DNA (1.8 mg HA DNA vaccine +0.2 mg
GM-CSF) (Figure 1B) were precipitated onto 1.0 mg of 1–3 mM
gold particles. The commercial prototype ND10 device is a
disposable, single use delivery device (Figure 1C) that contains a
helium gas microcylinder, an expansion chamber with a cassette
containing the DNA vaccine-coated gold particles, nozzle, and
actuation button (Figure 1D). To administer the vaccine, the
nozzle of the device cover is pushed down against the skin. This
action over-rides the button safety catch allowing the button to be
depressed only when the nozzle is in position. Pressing the button
breaks the tip off the gas microcylinder, releases the helium gas,
bursts the vaccine cassette, and forces the particles down the
nozzle and into the epidermal layers of the skin (Figure 1D).
Delivery into the skin of the inner thigh of rhesus macaques
resulted in transient erythema at the site of inoculation (Figure 1E).
The redness resolved within 24 hours after delivery and then faded
by 8 weeks post-administration (Figure 1F). This transient skin
reaction to PMED delivery using the ND10 device in nonhuman
primates is consistent with skin reactions to PMED reported in
humans [40]. Histological analysis of the skin site in biopsies
excised 24 hours post-delivery showed significant particle pene-
tration in the epidermis of the skin (Figure 1G), a result that is
consistent with the level of penetration required for optimum
immunogenicity of PMED DNA vaccines [6,7].
Rhesus macaques received particle-mediated epidermal immu-
nizations over the inguinal lymph node with the ND10 device.
Each macaque received a total of 12.0 mg/dose of a DNA vaccine
expressing the influenza A hemagglutinin gene (HA) either alone
(N=6) or in combination with a second plasmid expressing rhesus
macaque GM-CSF (HA+GM-CSF, N=6). The 12.0 mg DNA
vaccine dose was accomplished by delivering 6 targets per dose
consisting of 1.0 mg gold and 2.0 mg of DNA per target. Each
macaque received 3 doses (prime and 2 boosts) administered 8
weeks apart (weeks 0, 8, 16). The dose, immunization regimen and
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were previously determined to be optimum in rhesus macaques
and mice [41,42,43]. Blood, nasal, and tracheal secretions were
collected after each dose to analyze serum and mucosal antibody
and systemic T cell responses. Bronchioalveolar lavages were
collected after the 2
nd dose to analyze mucosal antibody and T cell
responses. Lung tissue and jejunum were also collected 8 weeks
after the final dose to analyze mucosal T cell responses.
GM-CSF increases serum antibody responses
Current influenza vaccines protect via induction of neutralizing
antibody specific for the viral HA. Serum from macaques as
various times post-vaccination was analyzed for the presence of
neutralizing antibodies by the hemagglutinin inhibition assay (HI).
Analysis of serum HI titers after the first immunization showed
that co-administration of GM-CSF accelerated the development of
A/New Caledonia/20/99 virus-neutralizing antibodies. By 4
Figure 1. Particle-mediated DNA vaccine delivery into the epidermis of rhesus macaques using the disposable commercial
prototype ND10 device. Plasmid DNA encoding (A) the gene for influenza A/New Caledonia/20/99 haemagglutinin (HA) was administered alone
or in combination with (B) a plasmid encoding the gene for rhesus macaque granulocyte-macrophage colony stimulating factor (rhGM-CSF) co-
formulated onto 1–3 mM gold particles. (C, D) The ND10 delivery device consists of a cassette containing 2.0 mg plasmid (1.8mg HA DNA+0.2mg GM-
CSF DNA) coated onto 1.0 mg of gold particles, a safety catch that is released when the device is held firmly against the skin surface, and an actuation
button that breaks the tip off a gas microcylinder and releases helium at high pressure. Release of the helium ruptures the cassette membrane,
entrains the DNA-coated gold particles into the helium jet, and propels them directly into cells in the skin. (E) Vaccinations were targeted to the skin
located on the upper inner thigh adjacent to the inguinal lymph node. Immediately following vaccination, vaccination sites are easily visualized as red
(erythema) targets in the skin. (F) The erythema is transient (24 hours) and vaccination sites faded but were still discernible at 8 weeks post-
vaccination. (G) Shown is gold particle penetration into the epidermal and dermal skin layers in a representative histological cross-section of a skin
biopsy collected 10 minutes after ND10 delivery.
doi:10.1371/journal.pone.0011021.g001
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GM-CSF group had detectable serum HAI titers ($1/20) whereas
antibody was not yet detectable in any of the 6 animals in the
unadjuvanted DNA vaccine group (Figure 2A). By 8 weeks and
prior to the first boost, 5 of 6 animals in the HA DNA only group
(25 mean titer, 65.0 SEM) and all 6 animals in the HA
DNA+GM-CSF group (40 mean titer, 68.9 SEM) had detectable
HI titers. Serum HI titers in both groups were increased following
the first boost to levels that clearly exceeded the minimum titer
associated with protection in humans (titer .40 HI). However, the
mean HI titer in the GM-CSF adjuvanted group after the first
boost was significantly higher than in HA DNA only group
(Figure 2B). The GM-CSF adjuvanted group also maintained a
significantly higher mean titer after the 2
nd boost. Four of the 6
macaques in the GM-CSF group developed titers .1000 after the
2nd boost whereas antibody titers in all 6 animals in the
unadjuvanted group remained below 1000 (Figure 2B). These
results show that PMED HA DNA vaccination was able to elicit
significant levels of neutralizing HA-specific antibodies in the
serum of immunized macaques. Furthermore, co-delivery of
rhesus GM-CSF as a genetic adjuvant with the HA DNA vaccine
accelerated the appearance of, and significantly increased the
magnitude of, neutralizing antibodies in the sera of immunized
animals.
GM-CSF increases T cell responses in the blood
T cell responses play an important role in clearing influenza
infections and in the development of a protective antibody response.
To determine the impact of GM-CSF on T cell responses,
lymphoproliferation (LPR) was measured in the blood after the
first and second vaccine dose following stimulation with recombi-
nant HA protein to determine the overall magnitude of the T cell
response independent of a specific cytokine effector function. As
shown in Figure 3A, only the GM-CSF adjuvanted group exhibited
a measurable HA-specific T cell proliferative response following the
prime. In addition, although both the GM-CSF-adjuvanted and
unadjuvanted groups developed strong HA-specific T cell prolifer-
ative responses after the first boost, co-delivery of GM-CSF DNA
notably enhanced the LPR in the blood.
As another means of measuring the T cell response elicited in
the GM-CSF-adjuvanted and unadjuvanted vaccine groups, an
ELISpot assay was used to enumerate the T cells in the blood of
vaccinated animals secreting IFN-c in response to stimulation with
pools of overlapping peptides derived from the full length A/New
Caledonia/20/99 HA protein. Similar to that observed with
serum antibody responses, the number of IFN-c secreting HA-
specific T cells in blood was found to increase in both the
unadjuvanted and GM-CSF adjuvanted groups following each
Figure 2. Induction of virus neutralizing antibodies in the sera
of macaques following immunization with either the unadju-
vanted, or rhGM-CSF adjuvanted, PMED HA DNA vaccine.
Influenza A/New Caledonia/20/99 virus-neutralizing antibodies present
in serum of macaques at the indicated times following vaccination with
HA DNA alone (black bars) or HA DNA co-delivered with rhGM-CSF
(hatched bars) were measured using a standard hemagglutination
inhibition (HI) assay. (A) Serum HI titers measured in individual animals
at the indicated times following the primary immunization at week 0.
Bars indicate the frequency of animals in each group (n=6) exhibiting a
HI titer greater than or equal to 1/20. Numbers above each bar indicate
the actual number of macaques in each group used to calculate the
frequencies. (B) Serum HI titers were measured in vaccinated animals
following boosting doses of vaccine at weeks 8 and 16 (indicated by the
arrows). Bars indicate the means (6 SEM) calculated for each group of
at the indicated times following vaccination. Indicated P values were
determined by the Mann-Whitney U test (two-tailed).
doi:10.1371/journal.pone.0011021.g002
Figure 3. Co-delivery of the GM-CSF genetic adjuvant enhanc-
es HA-specific T cell responses in the peripheral blood of PMED
HA DNA vaccinated animals. PBMCs were isolated from the blood
of macaques at the indicated times following the initial vaccination with
HA DNA (black bars) or HA DNA+rhGM-CSF (hatched bars). (A) T cell
proliferative responses in vaccinated macaques were measured by
incubating PBMCs with recombinant A/New Caledonia/20/99 HA
protein (1 mg/well) for 6 days prior to the addition of 1 mCi tritiated
thymidine. Bars represent the mean (6 SEM) stimulation index
calculated for each group of animals. (B) The number of HA-specific T
cells present in the blood of macaques after HA DNA vaccine priming,
the first boost, and second boost was measured by IFN-c ELISPOT assay.
Indicated P values were determined using the Mann-Whitney U test
(two-tailed).
doi:10.1371/journal.pone.0011021.g003
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responses detected in the GM-CSF adjuvanted group was
consistently higher than those detected in macaques vaccinated
with the HA DNA vaccine alone. In particular, animals in the
GM-CSF adjuvanted group exhibited over a 2-fold increase in the
mean number of IFN-c secreting HA-specific T cells in their
peripheral blood following the 2
nd booster immunization as
compared to animals in the unadjuvanted group (10,539 vs. 4,363,
respectively). Taken together, the LPR and ELISpot results show
that PMED HA DNA vaccination elicited strong HA-specific T
cell responses in the blood of rhesus macaques that were
significantly increased by the GM-CSF genetic adjuvant.
PMED influenza DNA vaccines induce mucosal antibody
responses in the respiratory tract
Mucosal IgA and IgG responses in the bronchioalveolar lavage
fluid (BALF) and nasal and tracheal secretions were analyzed by
ELISA using recombinant influenza A/New Caledonia/20/99
HA protein as the capture antigen. Following the first booster
immunization, HA-specific IgG responses were detected in BALF
(Figure 4A), but not in tracheal or nasal secretions (data not
shown). In contrast, HA-specific IgA responses were detected in
tracheal (Figure 4B) and nasal secretions (data not shown), but not
in the BALF (data not shown), following the second booster
immunization. The presence of a dominant HA-specific IgA
response in the upper respiratory tract and a dominant HA-
specific IgG response in the lower lung of vaccinated macaques is
consistent with the pattern of mucosal antibody induced following
influenza infections in mice [44,45]. A comparison of mucosal
antibody responses between the two vaccine groups showed that
mucosal HA-specific IgG responses were detected in the BALF
from just 2 out of the 6 macaques immunized with HA DNA alone
(R97 and R509) whereas all 6 macaques in the GM-CSF group
exhibited significant levels of mucosal IgG in their lungs. This
outcome correlates with a more rapid production of HA-specific
serum antibodies in the GM-CSF group (Figure 2) and suggests
that the presence of HA-specific IgG in the BALF following
PMED DNA immunization may result from the transudation of
IgG from the serum into the lung mucosa [46,47]. Mucosal HA-
specific IgA responses were detected in tracheal secretions from all
vaccinated macaques, with no significant difference noted between
the HA DNA only and GM-CSF adjuvanted vaccine groups
(Figure 4B). Analysis of the relative concentrations of total mucosal
IgG (BALF) and IgA (tracheal secretions) by ELISA showed no
differences in total mucosal immunoglobulin concentrations
between mucosal samples collected before and post vaccination
from each individual animal and no difference between the
unadjuvanted and GM-CSF adjuvanted vaccine groups (data not
shown) confirming that the observed increases in HA-specific
mucosal antibody in the BALF and trachea were due to the effects
of the vaccines. Together, these results demonstrate that PMED
immunization was capable of inducing HA-specific mucosal
antibody responses in both the upper and lower respiratory tract
of nonhuman primates but this effect appeared not to be
significantly impacted by co-administration of the GM-CSF
genetic adjuvant.
GM-CSF increases the magnitude and breadth of
mucosal T cell responses in the lung and gut
Delivery of vaccines into the skin by PMED has been shown to
induce T cell responses in both the blood and mucosal
compartments [17,48]. Accordingly, we next examined the
capacity of PMED HA DNA vaccination to elicit HA-specific T
cell responses in the lung and gut mucosa of immunized macaques.
HA-specific T cell responses in the lungs and jejunum of
vaccinated macaques 8–10 weeks following the final DNA
immunization (weeks 24–26 post-prime) were measured using an
IFN-c ELISpot assay. As shown in Figure 5A, only 1 out of 5
macaques from the unadjuvanted DNA vaccine group developed a
modest (,200 spot forming cells per10
6 lung lymphocytes) HA-
specific mucosal T cell response in the lung (Figure 5A, black bars).
In contrast, HA-specific mucosal T cell responses were detected in
the lung in 4 of 6 macaques in the GM-CSF adjuvanted group
(Figure 5A, hatched bars) with 3 of these animals exhibiting strong
mucosal T cell responses that exceeded 500 spot forming cells per
10
6 lung lymphoctyes. In the gut, mucosal T cell responses were
detected in all but 1 macaque in each DNA vaccine group but
similar to the lung, gut T cell responses in several animals
immunized with the GM-CSF adjuvant reached substantially
higher levels than levels observed in unadjuvanted group
(Figure 5B). Overall, the combined mucosal T cell responses that
developed in the lungs and guts of animals immunized with the
GM-CSF adjuvanted HA DNA vaccine were significantly higher
than in the unadjuvanted HA DNA vaccine group (P=0.031,
Mann-Whitney U test), supporting the concept that GM-CSF can
function as a mucosal adjuvant for DNA vaccines administered
into the skin.
Figure 4. Induction of mucosal antibody responses in the
respiratory tract of PMED HA DNA vaccinated macaques.
Bronchoalveolar lavage fluid (BALF) and tracheal swab samples were
collected from macaques prior to immunization and again at 4 weeks
following each boosting dose of the HA DNA vaccine, 6 rhGM-CSF. IgG
antibody responses in BALF (A) and IgA antibody responses in tracheal
swabs (B) against the A/New Caledonia/20/99 hemagglutinin protein
were detected by ELISA. Data are reported as the O.D. measured at
450 nm for each sample, diluted 1:20 in PBS, from individual immunized
animals.
doi:10.1371/journal.pone.0011021.g004
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infection or vaccination is thought to be a critical component in
protection against drifted strains of influenza virus [49]. To
determine if co-administration of the GM-CSF genetic adjuvant
influenced the breadth of the HA-specific T cell response elicited
in vaccinated macaques, lymphocytes isolated from the blood,
lungs, and guts of immunized animals were stimulated with 6
separate pools of overlapping HA peptides and analyzed for
responses against each pool in an IFN-c ELISpot assay. Each HA
peptide pool consisted of 23 to 24 15-mer peptides, overlapping by
11 amino acids, spanning the entire sequence of the HA protein.
As shown in Figure 5C, animals from both the unadjuvanted and
GM-CSF adjuvanted vaccine groups exhibited equally broad T
cell responses against each of the 6 peptide pools in the peripheral
blood. In the lung and gut mucosa, macaques immunized with HA
DNA alone exhibited mucosal T cell responses against just 2–3 of
the 6 total peptide pools (left panel), indicating that the repertoire
of HA-specific T cells induced in the mucosa of rhesus macaques
immunized with the unadjuvanted vaccine was narrower than the
repertoire of T cells detected in peripheral blood. Mucosal T cell
responses in the gut and lung of the unadjuvanted group were
dominated by responses against peptides in HA4 (aa 277–379) and
HA6 (aa 461–567), suggesting a similarity in the repertoire of T
cells elicited in these 2 distinct mucosal compartments. In contrast,
macaques immunized with the GM-CSF-adjuvanted HA DNA
vaccine (right panel) exhibited a broader repertoire of mucosal T
cell responses against all 6 of the HA peptide pools that was more
similar to the repertoire of T cells detected in the peripheral blood.
Together, these results suggest that co-delivery of the GM-CSF
genetic adjuvant was able to increase both the magnitude and
breadth of the HA-specific T cell response induced in the mucosa
following PMED HA DNA vaccination. These results also suggest
that the use of GM-CSF DNA as an adjuvant may overcome
barriers in compartmentalization of immune responses following
vaccination between the periphery (blood) and mucosa.
Impact of GM-CSF DNA co-delivery on the induction of
polyfunctional of HA-specific T cells in the periphery and
mucosa of PMED HA DNA vaccinated macaques
Recent studies indicate that polyfunctional T cells correlate with
durable protective immunity [50]. Furthermore, the quality of the
Figure 5. The GM-CSF genetic adjuvant increases both the magnitude and breadth of mucosal T cell responses elicited in the lungs
and guts following PMED HA DNA vaccination. HA-specific T cell responses in the (A) lung and (B) gut mucosa of macaques were determined
by IFN-c ELISpot assay 4–11 weeks after the final vaccination with HA DNA (solid bars) or HA DNA+GM-CSF (hatched bars). Individual bars represent
the peak number of HA-specific IFN-c T cells detected in the jejunum and lung tissue of individual animals 4–11 weeks after the final vaccination. (C)
Breadth of the IFN-c T cell response in PBMC, lung, and gut. HA-specific T cell responses in the indicated tissues were measured using a standard
IFN-c ELISpot assay with 6 individual pools of overlapping peptides (11 amino acid overlaps, 103 15-mers per pool) comprising the entire amino acid
sequence of the influenza A/New Caledonia/20/99 HA protein. The percent contribution of each peptide-pool specific response to the total response
was determined by dividing the mean number of IFN-c spot forming cells (SFC) measured against each individual peptide pool by the sum of the
response against all peptide pools. Results represent the average of 2 time-points tested after the 3
rd DNA dose (weeks 19 and 23). *Measurement
below positive threshold level for the assay.
doi:10.1371/journal.pone.0011021.g005
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clearance of respiratory infections, including influenza [51]. We
therefore sought to characterize the impact of co-delivering GM-
CSF DNA on nature and quality of the influenza HA-specific T
cell functional response in the lung and blood of the vaccinated
macaques. The relative contribution of HA-specific CD4+ and
CD8+ T cell subsets to the lung T cell response after the first
booster immunization and the blood T cell response after the
second booster immunization was determined by intracellular
cytokine staining of T cells stimulated with influenza A/New
Caledonia/20/99 HA peptide pools. Animals immunized with the
GM-CSF-adjuvanted DNA vaccine exhibited a trend toward a
higher frequency of HA-specific CD4+ T cells producing either
IFN-c, TNF-a, or IL-2 cytokines in both the lung (Figure 6A) and
blood (Figure 6B) when compared to animals immunized with the
HA DNA vaccine alone. The GM-CSF adjuvanted group showed
over a two-fold increase in the mean frequency of cytokine-
producing HA-specific CD4+ T cells in both the lung (2.58% vs.
1.19% ) and blood (3.39% vs. 1.23%) when compared to the
unadjuvanted group, although these difference fell short of
statistical significance due to the small number of animals per
group. Similarly, the frequency of cytokine-producing HA-specific
CD8+ T cells in the lung and blood tended to be higher in the
GM-CSF-adjuvanted vaccine group when compared to the
unadjuvanted group but this increase was not statistically
significant (Figures 6A and B).
We further characterized the nature of the T cell responses
induced by PMED HA DNA vaccination by assessing the relative
contribution of each cytokine (IFN-c, TNF-a, or IL-2) to the total
HA-specific CD4+ and CD8+ T cell responses. Figure 6C shows
that for both vaccine groups, TNF-a and IL-2 dominated the
CD4+ T cell cytokine response detected in the lung. This result
was markedly different from the pattern of cytokine expression by
HA-specific CD4+ T cells detected in the blood where the
response for both groups was dominated by IFN-c (Figure 6D).
For both the lung and blood, co-delivery of GM-CSF DNA with
the HA DNA vaccine augmented expression of the predominant
cytokine (TNF-a in the lung, IFN-c in the blood) in the CD4+ T
cell response. In characterizing the nature of the CD8+ T cell
response induced by vaccination, HA-specific CD8+ T cells
producing IFN-c, TNF-a, or IL-2 were detected in the lung
(Figure 6E) and blood (Figure 6F) of both vaccine groups. In both
the lung and blood, co-delivery of GM-CSF DNA tended to
reduce the proportion of CD8+ T cells expressing IL-2 and HA-
specific CD8+ T cells producing IFN-c and TNFa comprised a
greater portion of the total CD8+ T cell response in this group.
We next utilized Boolean analyses to determine the frequency of
HA-specific CD4+ and CD8+ T cells expressing one, two, or three
cytokines in the lung and blood of both vaccine groups. Figure 6G
shows that immunization with the HA DNA vaccine alone
induced a HA-specific CD4+ T cell response in the lung that was
comprised almost entirely of T cells expressing a single cytokine
(59%), with an almost equal distribution of cells expressing IFN-c,
TNF-a, or IL-2. The majority of the remaining HA-specific CD4+
T cells in the lungs of HA DNA vaccinated animals (40%) were
found to express two cytokines, with the pre-dominant phenotype
being co-expression of IL-2+ and TNF-a+. Co-administration of
the GM-CSF genetic adjuvant induced a modest, but discernable
increase, in the frequency of HA-specific CD4+ T cells in the lung
expressing all three cytokines (4% vs. 1%). However, the main
impact of GM-CSF on the nature of the CD4+ T cell response in
the lung of HA DNA vaccinated animals was centered on the
mono-functional cells. In contrast to the unadjuvanted group
where monofunctional responses were distributed fairly equally
between the cytokines, the majority of mono-functional HA-
specific CD4+ T cell response in the lungs of animals immunized
with GM-CSF expressed TNF-a (60%; Figure 6G).
Immunization with the HA DNA vaccine alone elicited mostly
HA-specific CD8+ T cells in the lungs expressing one cytokine
(69%; Figure 6G), with the remaining population (31%) found to
express two cytokines. As with the HA-specific CD4+ T cell
response, the majority of the dual-cytokine producing CD8+ T
cells in the lungs of animals from the unadjuvanted group
expressed IL-2 and TNF-a (Figure 6G). CD8+ T cells expressing
all three cytokines were not observed in the lungs of macaques
immunized with HA DNA vaccine alone. Similar to the effect on
the CD4+ T cell response, co-delivery of GM-CSF DNA increased
the frequency of mono-functional CD8+ T cells in the lung
expressing TNF-a when compared to the unadjuvanted group
(57% vs. 23%). This increase corresponded to a large decline in
the frequency of mono-functional CD8+ T cells expressing IL-2
(4% vs. 31%). However, similar to what was observed with the
CD4+ T cell response in the lung, co-administration of GM-CSF
DNA resulted in the appearance of polyfunctional HA-specific
CD8+ T cells expressing all 3 cytokines, IFN-c, TNF-a, and IL-2
(5%; Figure 6G). GM-CSF also appeared to alter the phenotype of
dual functional CD8+ T cells in the lung. In contrast to the
predominance of HA-specific CD8+ T cells expressing IL-2/TNF-
a in the lungs of animals from the unadjuvanted group, the
population of dual functional CD8+ T cells in the lungs of animals
from the GM-CSF adjuvanted group was comprised almost evenly
of IL-2+/TNF-a+ and IFN-g+/TNF-a+ CD8+ T cells (Figure 6G).
The pattern of cytokine expression by HA-specific T cells in the
blood (Figure 6H) was found to be markedly different from the
pattern we observed in the lung mucosa. Immunization with the
HA DNA vaccine alone induced a HA-specific CD4+ T cell
response in the blood that was comprised almost entirely of mono-
functional T cells expressing either IFN-c or IL-2 (43% and 33%,
respectively; Figure 6H). The remaining population of HA-specific
CD4+ T cells in the lungs of HA DNA vaccinated animals was
split almost evenly into dual- and triple-cytokine expressing cells
(13% and 11%, respectively). As with the CD4+ T cell response in
the lung, the main impact of GM-CSF on the nature of the CD4+
T cell response in the blood of HA DNA vaccinated animals was
an increase in the proportion of mono-functional cells. The mean
frequency CD4+ T cells in the blood of vaccinated animals
expressing IFN-c alone increased from 43% in the unadjuvanted
group to 69% in the GM-CSF adjuvanted group (Figure 6H).
Furthermore, the increase of IFN-c+ mono-functional CD4+ T
cells in the blood of the GM-CSF adjuvanted group corresponded
to a large decline in the frequency of mono-functional CD8+ T
cells expressing IL-2 when compared to the unadjuvanted group
(4% vs. 33%).
Similar to the CD4+ T cell response, immunization with the
HA DNA vaccine alone elicited a HA-specific CD8+ T cell
response in the blood that was comprised almost entirely of mono-
functional T cells expressing either IFN-c or IL-2 (38% and 44%,
respectively; Figure 6H). The remaining population of HA-specific
CD8+ T cells in the lungs of HA DNA vaccinated animals was
made up of dual- and triple-cytokine expressing cells (13% and
5%, respectively), with the majority of dual-functional CD8+ T
cells expressing IFN-c and IL-2. Co-administration of the GM-
CSF DNA induced a significant increase in the frequency of
mono-functional HA-specific CD8+ T expressing IFN-c in the
lungs of vaccinated macaques (mean of 84% in the GM-CSF
adjuvanted group vs. mean of 38% in unadjuvanted group). The
large increase in the frequency of IFN-c+ mono-functional CD8+
T cells corresponded to a loss of detectable mono-functional CD8+
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Intracellular cytokine staining was performed on BALF collected from both vaccine groups at 4 weeks after the first boost (panels on left), as well as
PBMCs from both vaccine groups collected 4 weeks after the second boost (panels on right) to measure the expression of IFN-c, TNF-a, and IL-2 by
CD4+ and CD8+ T cells after stimulation with overlapping peptides derived from the A/New Caledonia/20/99 HA protein. Bar charts show the mean
total percentage (+/2 SEM) of CD4+ and CD8+ T cells in the lungs (A) and blood (B) of animals from the unadjuvanted (black bars) and GM-CSF
adjuvanted (hatched bars) found to express IFN-c, TNF-a, or IL-2 following HA peptide stimulation. Indicated P values were determined using the
Mann-Whitney U test (two-tailed). Stacked bar charts show the mean proportion of cells producing IFN-c (black), TNF-a (gray), or IL-2 (hatched) to the
total HA-specific CD4+ and CD8+ T cell response detected in the lung (C, E) and blood (D, F) of animals from the unadjuvanted and GM-CSF
adjuvanted vaccine groups. Pie charts show the proportion of HA-specific CD4+ and CD8+ T cells in the lung (G) and blood (H) from both vaccine
groups positive for the different combinations of one, two, or three cytokines.
doi:10.1371/journal.pone.0011021.g006
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from the GM-CSF adjuvanted group. Co-delivery of GM-CSF
DNA appeared to slightly decrease the overall frequency of dual-
functional CD8+ T cells in the blood of vaccinated macaques but
modestly increase in the frequency of triple cytokine expressing
HA-specific CD4+ (16% in the GM-CSF adjuvanted group vs.
11% in the unadjuvanted group) and CD8+ T cells (8% in GM-
CSF adjuvanted group vs. 5% in unadjuvanted group). Taken
together, results from our Boolean analyses reveal considerable
differences in the nature and quality of the T cell responses
induced in the blood and lung mucosa following PMED HA DNA
immunization. Furthermore, co-delivery of the GM-CSF DNA
altered the functionality of HA-specific T cells but this effect
markedly differed between the two compartments.
Discussion
In this study we assessed the systemic and mucosa immunoge-
nicity of an influenza (A/New Caledonia/20/99) HA DNA
vaccine administered by particle-mediated epidermal delivery
(PMED or gene gun) in rhesus macaques. In addition, we
evaluated whether co-administration of the GM-CSF genetic
adjuvant could augment the immunogenicity of the PMED HA
DNA vaccine. The data show that PMED DNA vaccination
induced significant levels of hemagglutination inhibiting (HI)
antibodies and multi-functional HA-specific CD4+ and CD8+ T
cell responses in the periphery of macaques after priming and that
these responses increased after each subsequent boosting dose. In
addition, PMED HA DNA vaccination induced detectable levels
of HA-specific mucosal antibodies and T cells in the lung and gut-
associated lymphoid tissues of vaccinated macaques. Importantly,
our results reveal that co-delivery of plasmid DNA encoding the
rhesus macaque GM-CSF gene could significantly enhance both
the systemic and mucosal responses induced by PMED HA DNA
vaccination.
PMED DNA vaccines possess a number of features which may
allow them to overcome many of the perceived shortcomings of
the more conventional vaccination technologies. In addition to
antibody, PMED DNA vaccines induce T cell responses against
epitopes that are conserved across variant virus strains and may
thereby provide a second level of protection from illness if the
antibody response fails [52] and improve protective efficacy in the
elderly [39]. Further, the ability of PMED DNA vaccines to induce
mucosal immune responses could provide additional benefit by
limiting viral replication at the site of exposure. PMED DNA
vaccines have consistently demonstrated greater efficiency in
human clinical trials than DNA vaccines injected by needle or
liquid jet propulsion into the muscle. In these studies, PMED
elicited both T cell responses and protective levels of antibody in
100% of vaccinated subjects [28,40]. However, in comparing
results from hepatitis B and influenza PMED DNA vaccine clinical
trials where an existing licensed vaccine is available, antibody
responses induced by PMED arose more slowly, required more
doses, and/or reached titers that were lower than those historically
observed with licensed killed or recombinant protein vaccines
[28,29,40].
The present study utilized the same disposable clinical prototype
PMED device (ND10) previously tested for immunogenicity in a
clinical trial [29]. In this clinical study, subjects were vaccinated by
PMED with a trivalent (H1+H3+B) influenza HA DNA vaccine
and then challenged with an H3 strain of influenza. Vaccination
was safe and well-tolerated and elicited protection from challenge
in approximately 50% of subjects, providing the first proof-of-
principle of a DNA vaccine affording protection in humans.
However, efficacy was lower than reported for licensed vaccines
(70%) indicating that greater potency was required before the
PMED technology could match conventional influenza vaccines.
Our results here show that GM-CSF increased neutralizing
antibody titers to levels that substantially exceeded levels known
to afford protection against influenza in humans and significantly
accelerated seroconversion such that antibody responses were
detected in 100% of the macaques after only a single immuniza-
tion. This outcome strongly suggests that GM-CSF may provide a
means to overcome the problems of lower immunogenicity and
slower development of antibody responses observed with un-
adjuvanted influenza DNA vaccines in the clinic when compared
to existing licensed vaccine approaches.
GM-CSF was also found to both increase the induction of
peripheral and mucosal CD4+ and CD8+ T cell responses
following PMED DNA vaccination and influence the functionality
of those responses. We also observed that PMED DNA
immunization, with or without GM-CSF, elicited high frequencies
of mono-functional CD4+ and CD8+ T cells. IFN-c was the
predominant cytokine expressed by T cells in the blood, whereas
TNF-c dominated responses in the lung. It is currently not known
what role TNFa plays in controlling influenza infection but, like
IFNc, TNFa is known to have direct antiviral effects and is a
dominant cytokine produced during influenza virus infections
[51]. In addition, a recent study showed that induction of TNFa
responses may be important in the development of more effective
B and T cell recall responses against influenza suggesting that a
vaccine that enhances T cells with TNFa effector function may
influence its ability to confer durable immunity [53]. We also
found that GM-CSF increased the frequency of triple cytokine-
producing T cells in vaccinated macaques, an outcome that is
consistent with a previous effect of GM-CSF on an HIV DNA
vaccine [36]. However, our study shows that this effect was more
pronounced in the lung than in the blood. This finding is critical,
as multi-functional T cell responses have been correlated with
improved vaccine-mediated protection in the blood [50,54] and
may similarly influence mucosal protection against a disseminated
infection in the lung. An explanation for why the GM-CSF genetic
adjuvant apparently had diverse effects on the functionality of T
cell responses in the blood and lung of PMED HA DNA
vaccinated animals is unclear, but we hypothesize that it is likely
related to different effects of GM-CSF on antigen presentation.
Encounters with mature, Ag-bearing dendritic cells within
draining lymph nodes facilitate T cell activation, proliferation,
and differentiation to effector cells before migration out to the
periphery and mucosa. Moreover, recent studies have suggested
that T cell functionality, particularly cytokine production, is
dependent on the stimulating APC [55].
Previous findings by Lai et al. [33] showing IgA antibody
responses in rectal secretions of macaques immunized with a GM-
CSF-adjuvanted DNA vaccine provided the first indication that
GM-CSF may be able to enhance the mucosal immunogenicity of
DNA vaccines. However, the impact of GM-CSF on the induction
of mucosal antibody in the lung and T cell responses in the lung or
gut has not been previously studied. We and others have shown
that unadjuvanted SIV and influenza PMED vaccines induced
mucosal responses in mice, monkeys, and/or swine that were
associated with enhanced protection against either intranasal
challenges with influenza [14,18,48] or rectal challenges with SIV
[17]. We were therefore particularly interested to determine if
GM-CSF influenced the ability of PMED to induce mucosal
responses. The present study is the first to show that GM-CSF can
function as a strong mucosal adjuvant when co-administered to the
skin with an influenza DNA vaccine enhancing both the frequency
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breadth, and function of T cell responses in the lung and gut. Skin
immunization has been shown to be superior to parenteral
immunization for induction of both systemic and mucosal immune
responses [56,57], but the mechanisms whereby immune respons-
es are induced in mucosal compartments distant from the initial
skin site of vaccine administration are still unclear. Studies in mice
suggest an important role for antigen presenting cells in the skin in
the induction of mucosal responses [20,22,58], and GM-CSF is a
key cytokine influencing the maturation and migration of APC
including epidermal Langerhans cells [59]. Thus, two possibilities
currently under study in our laboratory is that GM-CSF enhances
mucosal immunogenicity of skin-delivered PMED influenza DNA
vaccines by increasing the migration of antigen presenting cells
bearing skin-derived antigen to mucosal compartments [20] and/
or enhances the ability of skin-derived APC to imprint a mucosal
homing phenotype on stimulated T cells [60].
Interestingly, our results showed that GM-CSF increased the
breadth of peptide-specific T cell responses in the gut and lung
mucosa but not the blood, an outcome that supports both possible
mechanisms. A broader T cell response in the mucosa may enhance
control of viral replication by targeting multiple epitopes expressed
by the homologous virus, as well as potentially shared HA epitopes
among drifted or shifted influenza viruses. Although we did not
perform fine epitope mapping of the HA-specific T cell responses
detected in vaccinated animals, it is noteworthy that the level
of sequence homology between the HA protein of A/New
Caledonia/20/99 and the HA proteins of drifted strains of H1N1
virusmaybehighenoughtosupporttheexistenceofcross-reactiveT
cell epitopes. For example, sequence alignment shows that the HA
protein of A/New Caledonia/20/99 shares 97% sequence homol-
ogy with A/Brisbane/59/2007, 97% homology with A/Solomon
Islands/03/2006, and 80% homology with A/California/04/2009
[61]. In considering the potential capacity of PMED HA DNA
vaccination to elicit cross-reactive T cell responses able to recognize
HA proteins from shifted strains of virus, it is notable that the
addition of the GM-CSF adjuvant increased T cell responses
against regions of the A/New Caledonia/20/99 HA protein
found to exhibit sequence homology with the HA protein of the
H5N1 A/Vietnam/1203/04 avian strain of influenza. ClustalW2
alignment analyses revealed ,80% sequence homology between
these two strains for peptide pool HA5 and ,75% sequence
homology for peptide pool HA6 [61]. Challenge studies ina relevant
mucosal infection model will beneeded to determine the significance
of this effect with respect to improving vaccine protection against
both drifted and shifted strains of influenza. It will also be important
to examine the effect of GM-CSF on the T cell responses against
more conserved influenza viral antigens (i.e., nucleoprotein and
M2e) that could further improve cross-protection against a wide
variety of influenza A viruses.
Previous clinical trials using injections of GM-CSF protein as
an adjuvant have been largely disappointing with some trials
showing no enhancement of systemic T cell or serological
immunity to co-delivered vaccines [62,63] although these trials
did not assess mucosal responses. The beneficial systemic and
m u c o s a le f f e c t so fG M - C S Fi nr h e s u sm a c a q u e si nt h ep r e s e n t
study may be due to co-delivery of GM-CSF as a plasmid with
the DNA vaccine directly into antigen presenting cells in the
skin [6]. In this setting, the GM-CSF adjuvant is expressed at
the same site, in the same cells, and with similar kinetics as the
target vaccine antigen and may have more direct effects on
enhancing antigen presentation and T cell activation. Whether
these effects translate from rhesus to man can only be assessed
by clinical trials.
Mucosal immune responses can contribute to vaccine efficacy
by blocking or limiting viral replication at the site of exposure and
the discovery of new vaccines that elicit mucosal immunity is
currently of significant interest [64,65]. To date, most experiments
in nonhuman primates have focused on measuring vaccine
responses and immune correlates of protection primarily in the
blood. Recent studies have started to investigate the capacity,
especially for candidate AIDS vaccines (HIV or SIV), to induce
mucosal responses in the lung [66] or gut [64] as a means to
determine the possible contribution or correlation of these
responses to protection. The study reported here provides a broad
comparison of the magnitude, nature, and breadth of T cell
responses induced by a DNA vaccine in the blood, lung, and gut of
rhesus macaques and shows there can be significant differences in
each compartment. These findings emphasize that immune
responses measured only in the blood may not fully represent a
vaccine’s immunogenicity and potential for protective efficacy
against mucosally transmitted diseases. A vaccine technology
capable of inducing both antibody and improved anti-influenza T
cell responses, especially at mucosal surfaces where influenza
infection takes place, may provide superior protection. A further
potential advantage of this technology for pandemic preparedness
is the speed with which a new DNA vaccine can be synthesised
and manufactured. The time taken to deploy a novel influenza
vaccine may have a critical influence on the mortality of a
developing pandemic, and the avoidance of use of eggs, live viruses
and mammalian cell culture in the manufacture of DNA vaccines
may provide greater surety of production and a more rapid
response than more conventional influenza vaccine technologies.
The ease of manufacture together with the improved systemic and
mucosal immunogenicity reported here support further develop-
ment of particle-mediated DNA vaccines in combination with
GM-CSF as a clinically-viable approach for improving vaccination
against influenza.
Materials and Methods
Ethics Statement
The University of Pittsburgh takes responsibility for humane
care and use of laboratory animals in all research projects
including those awarded by the Public Health Service. They are
committed to comply with the Principles for Use of Animals, the
National Institute of Health Guide for the Care and Use of
Laboratory Animals, the Provisions of the Animal Welfare Act,
and other applicable laws and regulations which are consistent
with the recommendations of the Weatherall report ‘‘The use of
non-human primates in research’’. The university’s Statement of
Assurance is on file with the PHS, Office for Protection from
Research Risks (A3187-01). The University of Pittsburgh is
accredited by the American Association for the Accreditation of
Laboratory Animal Care International (AAALAC). All experi-
mental manipulations were approved by the University’s Institu-
tional Animal Care and Use Committee (approval # 0711526).
Animals were cared for by well established, competent clinical
veterinary and animal caretaker staff. Animal discomfort and pain
was alleviated by appropriate and routine use of anesthetic and/or
analgesic agents.
Influenza A/New Calendonia/20/99 HA DNA vaccine
(pPML7800)
The HA coding sequence was synthesized at GeneArt (Regens-
burg, Germany) from the full-length amino acid sequence of the
influenza A/New Caledonia/20/99 (H1N1) hemagglutinin (HA)
protein obtained from the Influenza Sequence Database (http://
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human genes (http://www.kazusa.or.jp/eng/index.html). Plasmid
pPML7800wasgeneratedbyinsertingthecodon-optimized H1HA
gene into an expression cassette (pPJV7563) that uses the human
cytomegalovirus immediate early promoter. Additional sequences
were included to improve expression, specifically the HBV pre-S2
59 UTR, CMV exon K (consisting of the first two CMV IE exons
spliced together by deletion of the natural intron), rat insulin intron
A, HBV env enhancer, and rabbit beta globin poly A (rGpA).
Expression of the HA antigen from pPML7800 was confirmed
in B16 melanoma cells (ATCC, Manassas, VA). Cells were
transfected with pPML7800 using LipofectinH (Invitrogen, Carls-
bad, CA) according to manufacturers’ instructions. At eighteen
hours post transfection, cells were fixed with a 50/50 mixture of
methanol/acetone and blocked with 5% dry milk/TBS (Bio Rad
Laboratories, Melville, NY). The cells were probed with a 1/3,000
dilution of sheep antisera raised against New Caledonia (CBER,
Rockville, MD) in 1% dry milk/TBS/0.05% Tween-20 (Sigma-
Aldrich, St. Louis, MO), followed with a 1:1,500 dilution of rabbit
anti-sheep/biotin (KPL, Gaithersburg, MD) in 1% dry milk/
TBS/0.05% Tween-20, and finally with a 1/1,800 dilution of
streptavidin/HRP conjugate (KPL, Gaithersburg, MD) in TBS/
0.1% Tween-20. Color was developed using tetramethylbenzidine
substrate (TMB; Sigma). The reactions were stopped with 1N
H2SO4, and 200 microliters were aliquoted to an ELISA plate
and read at 450nm. Successful expression of the HA antigen in
transfected B16 cells was confirmed by an absorbance reading six
times greater than the reading obtained with non-transfected cells.
Rhesus GM-CSF genetic adjuvant vector
The rhGM-CSF coding sequence for plasmid pPML7842 was
synthesized at GeneArt (Regensburg, Germany) using the published
amino acid sequence for Macaca mulatta GM-CSF [67]. The codon-
optimized gene was inserted into expression cassette pPJV7563 as
described for pPML7800. Expression of rhesus macaque GM-CSF
from pPML7842 was confirmed in B16 melanoma cells following
LipofectinH transfection using a similar method to the one described
above for pPML7800 substituting the use of a biotinylated anti-
human GM-CSF monoclonal antibody (BioLegend, San Diego,
CA) cross-reactive to rhesus macaque GM-CSF.
Rhesus macaques
Adult male Indian origin rhesus macaques (Macaca mulatta) were
obtained from an approved vendor. All procedures were
performed under sedation with ketamine (Parke-Davis, Ann
Arbor, MI) (10mg/kg). Bronchial alveolar lavages (BAL) were
performed on anesthesized animals pre-oxygenated to induce
blood oxygen saturation levels of .95%. Glycopyrolate at
0.01 mg/kg was administered intra-muscularly (IM) prior to the
insertion of a pediatric bronchoscope. Immediately following
insertion of the bronchoscope, 2–3 ml of 1% sterile Lidocaine was
infused into the lung. To harvest the BAL fluid, 10 ml aliquots of
sterile 0.9% bacteriostatic saline was infused into the lung via the
bronchoscope and aspirated to remove. Oxygen was again
administered immediately following the procedure to maintain
blood oxygen saturation levels of .95%. Tracheal swabs were
collected using a cotton tip applicator and the secretions collected
were suspended in 0.5ml saline. Nasopharyngeal specimens were
collected by instillation of 0.5 ml saline into each nare. Jejunal
resections (10–15 cm) and lungs were collected at necropsy.
ND10 PMED DNA vaccine immunizations
Plasmid DNA was precipitated onto 1–3 mm gold particles as
previously described [40] at a rate of 1.8 mg pPML7800 and
0.2 mg pPML7842 (10:1 ratio of DNA vaccine to adjuvant) per
1.0 mg of gold. Animals were sedated with ketamine (10 mg/kg;
Parke-Davis, Ann Arbor, MI), the inner leg fur was clipped, and
DNA-coated gold particles were accelerated into the skin of both
the abdominal and inguinal lymph node regions using a single use,
disposable ND10 clinical particle-mediated epidermal delivery
(PMED) device (PowderMed, Ltd., Oxford, U.K.) to deliver the
DNA directly into the cells of the epidermis as described [29].
DNA-coated gold particles were delivered at a helium pressure of
45 bar psi. Each actuation resulted in the delivery of 1.0 mg of
gold and 2.0 mg of DNA into the epidermis. A single dose
consisted of a 12.0 mg of total DNA (10.8 mg HA DNA vaccine
and 1.2 mg GM-CSF genetic adjuvant) per immunization and was
achieved by using 6 disposable devices to administer 6 actuations
into the skin of the inner thigh. Each of the 3 doses was
administered 8 weeks apart.
Isolation of mononuclear cells from blood, lung, and
jejunum
Rhesus macaque peripheral blood mononcuclear cells (PBMC)
were isolated by Ficoll density gradient centrifugation, erythro-
cytes removed using ACK Lysing buffer (BioWhittaker, Walkers-
ville, MD), and remaining cells washed 3 times with RPMI-1640
media (BioWhittaker) supplemented with 10% fetal bovine serum
(Life Technologies, Gibco BRL) (R10). Bronchoalveolar lavage
fluid (BALF) cell suspensions collected at necropsy were obtained
by instilling and aspirating 150 ml of PBS into the main bronchus
of each lung. BALF cells collected by either bronchoscope or at
necropsy were pooled and concentrated by centrifugation, washed
twice in HBSS (Ca
2+/Mg
2+-free; Cellgro/Mediatech; Fisher
Scientific, Federal Way, WA), and then resuspended in R10
media. Mononuclear cells were isolated from jejunal resections
using a mechanical and enzymatic (dispase) extraction protocol as
described [17,68], with mononuclear cells released from the
lamina propria (lamina propia lymphocytes or LPL) then purified
using Percoll gradient separation.
Histology
Bead penetration into the skin of rhesus macaques was tested
prior to vaccination in 2 macaques. One milligram of placebo gold
(no DNA) was delivered into the skin. Each vaccine site was then
removed by 8 mm punch biopsy 10 minutes following vaccination
for cross sectioning. Skin biopsies were frozen in liquid nitrogen
after embedding in PolyFreeze tissue freezing media (Polysciences,
Inc., Warrington, PA). Frozen skin samples were cryostatically cut
into 10 mm sections, fixed with a mixed solution of formalin/acetic
acid/methanol, and then stained with Gill’s Haematoxylin and
Eosin (H&E) to allow visualization of gold particle penetration and
distribution.
Hemagglutination inhibition assay
RDE (Accurate Chemical & Scientific Corp., Westbury, NY)
treated sera were analyzed for the presence of influenza A/New
Caledonia/20/99 specific antibody using a hemagglutination
inhibition (HI) assay as described [29]. Briefly, two-fold serial
dilutions of RDE-treated sera were incubated with four hemag-
glutination units of influenza A/New Caledonia/20/99 virus
propagated in 11-day old embryonated eggs followed by the
addition of turkey erythrocytes. Serum HAI titers are reported
from the average of duplicate tests as the reciprocal dilution of
serum found to inhibit hemagglutination. A titer of 5 was assigned
to those serum samples that failed to inhibit hemagglutination at
the starting dilution of 1/10.
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HA-specific IgG and IgA antibody levels in macaque nasal
washes, tracheal swabs, and bronchoalveolar lavage fluid (BALF)
were assessed by enzyme-linked immunosorbent assay (ELISA).
RIA/EIA plates (Corning-Costar) were coated with 31 ng/well of
recombinant baculovirus-expressed A/New Caledonia/20/99
(Protein Sciences, Meriden, CT) overnight at 4uC, blocked with
10% FBS in PBS for 1 h at room temperature, and then washed
three times with wash buffer (PBS-T; phosphate-buffered saline
containing 0.05% Tween 20). Two-fold serial dilutions of samples
were added to the wells and plates were incubated for 2–3 hrs at
room temperature. Following three washes with PBS-T, plates
were incubated with horseradish-peroxidase conjugated goat anti-
macaque IgG (1/5,000 dilution) or IgA (1/4,000 dilution)
secondary antibodies (Nordic Immunological Laboratories, The
Netherlands) for 1 h at room temperature. After three washes with
PBS-T, TMB substrate (Sigma-Aldrich) was added to the wells for
30 min at room temperature. Color development was stopped by
the addition of 1 N H2SO4, and the plates were read at 450 nm.
ELISA data from tracheal swab and BALF samples are reported as
the OD450 nm reading obtained from a 1/20 sample dilution in
sterile PBS. The 1/20 sample dilution was found to yield the least
amount of background in addition to absorbance values greater
than the threshold level of our ELISA assay.
The relative concentrations of IgG and IgA immunoglobulin in
mucosal samples were assessed by direct ELISA. RIA/EIA plates
(Corning-Costar) were coated overnight with two-fold serial
dilutions of BALF (starting at 1/5 in PBS) and tracheal swab
(starting at 1/10 in PBS) samples collected from individual
macaques before and after vaccination. Wells were blocked,
washed, and then incubated with horseradish-peroxidase conju-
gated goat anti-macaque IgG or IgA secondary antibodies (Nordic
Immunological Laboratories) as described above. TMB substrate
was added after incubation with detecting antibody and three
washes with PBS-T. Color development was stopped using 1 N
H2SO4. Data are expressed as the OD450 nm reading obtained at
the indicated serial dilution of sample.
Lymphoproliferation assay
Lymphoproliferative responses were measured using
3H-thymi-
dine assay as previously described [69]. Briefly, whole PBMCs were
cultured in triplicate wells at 2610
5 cells per well in a total volume of
200 ml of AIM-V medium (Invitrogen), in the presence of 0.2 mgo f
recombinant A/New Caledonia/20/99 HA protein (Protein Scienc-
es, Meriden) for 6 days at 37uC, 5% CO2.
3H-labeled thymidine
(1.0 mCi, Perkin-Elmer, Waltham, MA) was then added to each well
and harvested after 18–20 hrs onto 96-well Unifilter GC plates
(Packard Bioscience, Meriden, CT).
3H-labeled thymidine incorpo-
ration was measured using a Topcount liquid scintillation counter
(PackardBioscience)andresultsexpressedasstimulationindices(S.I.),
defined as the ratio of the mean counts per minute (cpm) of wells
incubated with HA antigen to the mean cpm of wells incubated with
medium alone. Controls included media alone and concanavalin A
(ConA, Sigma) used at a final concentration of 5 mg/ml.
IFNc Enzyme-Linked Immunospot (ELISpot) Assay
Cells isolated from peripheral blood, BALF, or jejunum were
stimulated with 6 individual pools of peptides (1mg total peptide/
ml) spanning the hemagglutinin (HA) protein of the A/New
Caledonia/20/99 (H1N1) strain of influenza virus (Mimotopes,
Victoria, Australia). Peptides were 15mers overlapping by 11
amino acids and each pool contained 23–24 individual peptides.
Concanavalin A (Sigma) was used for positive control wells (5mg/
ml final) and media supplemented with 80% DMSO for negative
control wells. HA-specific T cells secreting IFN-c were detected by
ELISpot assay using paired anti-macaque IFN-c monoclonal
antibodies (U-Cytech-BV, The Netherlands) as described [40,69].
Spot forming cells (SFC) were enumerated using an ImmunoSpotH
Analyzer with CTL ImmunoSpotH Professional Software (Cellular
Technology Ltd., Shaker Heights, OH). Results are expressed as
the mean number of SFC in replicate wells containing peptide
minus the mean number of SFC in wells containing media/80%
DMSO. Responses significantly higher than background levels
(twice the number of SFCs enumerated in wells containing
untreated cells plus 10 spots) were considered positive.
Intracellular Cytokine Staining
Cells isolated from peripheral blood (fresh or cryo-preserved
PBMCs) or BALF (fresh) collected from immunized macaques were
incubated with pools of over-lapping15-mer peptides (1 mg/ml of
each peptide final) derived from the HA protein of the influenza A/
New Caledonia/20/99 virus at a concentration of 10
6 cells/well,
together with 0.5 mg each of the anti-human CD28 (clone CD28.2)
and anti-human CD49d (clone 9F10) co-stimulatory antibodies
(both fromBD Biosciences, San Jose, CA) ina totalvolumeof 200 ml
ofAIMV media. Cells wereincubated with 5 mg/mlofSEB (Sigma-
Aldrich) as a positive control or media supplemented with 80%
DMSO as a negative control. After incubating for 1 hr at 37uC, cells
were treated with 10 mg/ml of Brefeldin A (Sigma-Aldrich) and
incubated for 5 hrs at 37uC. Plates were then wrapped in foil, stored
at 4uC overnight. Cells were then washed twice with FACS buffer
(PBS containing 2% FBS) and stained with APC-Cy7 conjugated
anti-rhesus CD8 (clone RPA-T8), PerCP conjugated anti-rhesus
CD4 (clone L200), and Pacific Blue
TM conjugated anti-rhesus CD3
antibodies (clone SP34-2) in AIM-V medium. Cells were then fixed
using BD Cytofix/Cytoperm
TM solution and permeabilized using
BD Perm/Wash buffer
TM (both from BD Biosciences). Permeabi-
lized cells were then stained with PE conjugated anti-human IL-2
(clone MQ1-17H12), APC conjugated anti-rhesus TNF-a (clone
MAb11), and PE-Cy7 conjugated anti-human IFN-c (clone 4S.B3)
antibodies in Perm/Wash buffer. Following intracellular staining,
samples were washed with FACS buffer (PBS +0.5%BSA+0.05%
sodium azide) and then resuspended in 4% paraformaldeyde
(Electron Microscopy Solutions). Approximately 250,000 events
werecollected on a LSR II flow cytometer(BD Biosciences)and data
was analyzed using FlowJo v7.5 software (Tree Star, Inc., Ashland,
OR). Unless otherwise specified, all antibodies were obtained from
BD Biosciences. All flow cytometric staining data are reported after
subtraction of the background level of staining.
Statistical analysis
Statistical analyses were performed using GraphPad 5.03
statistical software program. Where indicated, statistical signifi-
cance was assessed using the two-tailed Mann-Whitney U test. P
values #0.05 were considered significant.
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